‘Potential Detrimental Effect’ With Fourth-Line Olaparib in Ovarian Cancer
NEW YORK — A post-hoc analysis of overall survival (OS) in the SOLO3 trial demonstrated why olaparib (Lynparza) recently had its fourth-line indication in ovarian cancer pulled by drugmaker AstraZeneca. The phase III trial, which tested olaparib versus non-platinum chemotherapy for women with BRCA-mutated platinum-sensitive relapsed disease, found diverging OS signals based on whether women […]